Opendata, web and dolomites

SYN1002

A New Therapeutic Option to Protect Central Nervous System against Acute Ischemic Stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYN1002 project word cloud

Explore the words cloud of the SYN1002 project. It provides you a very rough idea of what is the project "SYN1002" about.

stage    sales    share    suitable    net    plasminogen    stroke    complement    pharmaceutical    patient    match    proof    framework    pathologies    causing    agent    clinical    larger    persons    2017    16    substance    peptide    treatments    deal    markets    million    business    safety    patients    each    peak    indication    syn1002    initially    protect    auto    treatment    preclinical    neuronal    therapeutic    intends    feasibility    six    millions    billion    2012    rtpa    event    immune    thrombolytic    permanent    experiencing    efficient    265m    licensing    pioneer    seed    health    world    positioning    administered    inflammatory    of    neuroprotective    market    drug    ais    solution    potent    treat       biotech    draw    institutes    qualify    tissue    2026    industry    acute    tolerability    iia    disability    stoke    ischemic    time    damage    anti    400m    suffering    approved    safe    deaths    perfect    company    50    realize    doses    documenting    limited    ongoing    recombinant    applicable    confirming    search    successfully    orphit    strokes    activator    plan    window    multiple   

Project "SYN1002" data sheet

The following table provides information about the project.

Coordinator
ORPHIT 

Organization address
address: 1093 CHEMIN DES PLATEAUX FLEURIS RESIDENCES PANORA LA B
city: SAINT-LAURENT-DU-VAR
postcode: 6700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.orphitpharma.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2018-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ORPHIT FR (SAINT-LAURENT-DU-VAR) coordinator 50˙000.00

Map

 Project objective

Each year, about 16 million strokes occur in the world causing millions of deaths and one third of patients experiencing permanent disability. The main treatment of stroke is thrombolytic agent recombinant tissue plasminogen activator (rtPA). Not all the patient can qualify for this treatment and it can be administered only in a limited time window. No existing drug is approved to protect against ongoing neuronal damage after the acute event. In this framework, our company, ORPHIT, a seed-stage biotech company, intends to be a pioneer by bringing clinical proof of concept of our peptide SYN1002 as suitable neuroprotective anti-inflammatory agent to treat stoke in acute phase that could be administered at multiple doses as complement to current thrombolytic treatments and also in patients who do not qualify for treatment with rtPA. This peptide is our lead product and has been initially developed as a potent anti-inflammatory substance in auto-immune pathologies with a clinical phase 1 study successfully documenting the safety and tolerability. Its properties make it a perfect match with current needs on Stroke treatment. Therefore, our solution is of interest for the pharmaceutical industry and health institutes who are currently in the search of a treatment that would be efficient and safe enough to be applicable to a larger part of the persons suffering from Stroke. The acute ischemic stroke (AIS) therapeutic market generated 400M€ in 2012 across the six major markets and is expected to reach 1.1 billion € by the end of 2017. SYN1002 sales at peak (2026) are expected to achieve 50% of market share, and a licensing deal at end of phase IIa would come out with a net present value of 265M€ for our company. In order to achieve this goal ORPHIT will realize a feasibility study aiming at strengthening SYN1002 preclinical package in AIS indication, confirming drug positioning through in depth market study, and draw a European business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYN1002" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYN1002" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SINUSLIGHT (2018)

Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More